Vivodyne’s Post

Transforming a global biotech company like Biogen involves navigating complex challenges and making strategic decisions. In a recent conversation with BCG’s Torben Danger, Biogen CFO Mike McDonnell discusses its Fit for Growth initiative. My key takeaways: 1. Core Focus: Prioritizing top-line growth, margin expansion, and efficient capital allocation is crucial for management. 2. Employee Engagement: Empowering employees to redesign their organizations fosters creativity and maintains an entrepreneurial spirit. 3. Strategic Investments: Acquisitions like Reata Pharmaceuticals highlight Biogen's commitment to innovative treatments and diversification into rare diseases. 4. AI Implementation: Leveraging AI for efficiency, particularly in R&D, underscores the potential of technology to drive growth and innovation. To learn about Biogen's impressive people first transformation journey, read the full interview -   #CostManagement

When building a company-wide approach to extending your Life Sciences cash runway, CFOs and leadership teams must do the following:    - Understand investor expectations - Spend cash on what matters - Evaluate different scenarios for funding growth - Focus on right now   FLG Partners, Andrew Levitch and Patrick Nugent provide some great advice on this in this second in our four-part series - read more here: https://lnkd.in/g-YKeP8X #lifesciencecfo #cashmanagement 

As the dust settles from years of soaring valuations, our focus shifts to new expectations in 2024. At #LSIUSA24, our expert panelists will unpack the latest developments in valuation and financing, sharing forecasts and current trends that address the 2024 outlook, and provide a deep dive into how these shifts will affect both current and future investment landscapes. We’ll hear perspectives from: • Rik Vandevenne (Moderator), Managing Director, RC Capital, a Healthcare focused growth equity fund, currently investing out of its seventh fund. • Rebecca Raabe, Investment Partner, SPRIG Equity, a growth equity and late-stage venture capital firm dedicated to improving patient outcomes by partnering with best-in-class teams and technologies in the medical technology sector. • Paul McCreadie, Partner & COO Arboretum Ventures, a venture capital firm specializing in the healthcare sector investing throughout the United States, but with a preference for Midwest opportunities. • Matthew Schopp, Senior Director, Business Development, Zimmer Biomet, a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We are still accepting registrations for LSI USA ‘24 on March 18-22 in Dana Point, California. Visit our website to learn more and secure your spot: https://lnkd.in/gjgMpMBh

Demystifying Transferrable Economics - John Kasian, CPA, MSA's "hands-on, practical presentation demystified the complex topic of financial story telling within confidential pitch decks. From mapping out a Funding Timeline to detailing the ins and outs of Series A and B financing, Kasian provides a blueprint for success that our members found invaluable." - CEOthreesixty #lifesciences #biotechnology #pharmaceuticals #medicaldevices #venturecapital #capitalraising

🌟 Exciting Insights from Our Latest CEO360 Life Sciences Group Meeting 🌟 Last month, our CEO360 Life Sciences group had the privilege of hosting John Kasian, CPA, MSA from Sayva Solutions, who illuminated the path on one of the most critical yet overlooked areas for early-stage Life Sciences CEOs: Transferrable Economics Understanding how to communicate the financial value of your company to investors is a cornerstone of success. It's not just about having innovative ideas; it's about showcasing how these ideas translate into viable, financial gains for investors. Special thanks to Tari Suprapto, David H. Crean, and John Foley, for leading the charge in guiding early-stage CEOs through the intricate journey of pre-Seed, Seed and Series A capital financing. Their expertise, combined with Sayva's unparalleled experience in preparing financial statements for over 300 Life Sciences startups, offers our CEO members and sponsor partners a treasure trove of knowledge and practical advice. John Kasian's hands-on, practical presentation demystified the complex topic of financial storytelling within confidential pitch decks. By demonstrating a clear, convincing, and realistic financial narrative through just four meticulously designed slides, Kasian provided a blueprint for success that our members found invaluable. From mapping out a Funding Timeline to detailing the ins and outs of Series A and B financing, Kasian's approach is a masterclass in clarity and precision that speaks volumes to investors. A heartfelt thank you to John Kasian for this enlightening session and to our partner sponsors and advisors in the ecosystem, including Catalent Pharma Solutions, Procopio, Cory, Hargreaves & Savitch LLP, Deloitte, Ty Summerlin, CFP®, Arrow Up Partners, LLC, and Cardiff Advisory LLC. Your support and expertise continue to empower our Life Sciences community. Let's continue to foster innovation, share knowledge, and drive forward the life sciences sector. Together, we're making a difference! #mentoring #lifesciences #biotechnology #pharmaceuticals #medicaldevices #peeradvisory #venturecapital #capitalraising

📢 Exciting insights on MedTech M&A trends from Oaklins' Q1 report, including a shoutout to Healthcare Holding Schweiz AG for our strategic acquisition of MIKRONA GROUP Ltd. 🚀 Check out the full post to stay ahead in the game! #MedTech #HealthcareHolding #MergersandAcquisitions #SwissMA

Corner-office newcomers: 1st-time CEOs discuss challenges of running a biotech. There are common challenges including personal (loneliness at the top and balancing work/family), unearthing "blind spots" and measuring success: https://bit.ly/3YFPumC

𝐅𝐫𝐨𝐦 𝐊𝐧𝐨𝐜𝐤𝐨𝐮𝐭 𝐭𝐨 𝐂𝐨𝐦𝐞𝐛𝐚𝐜𝐤: 𝐇𝐨𝐰 Boston Scientific 𝐏𝐮𝐥𝐥𝐞𝐝 𝐚 𝐑𝐨𝐜𝐤𝐲!   𝐓𝐡𝐞 𝐊𝐧𝐨𝐜𝐤𝐨𝐮𝐭 𝐏𝐮𝐧𝐜𝐡   In Jan 2006, Boston Scientific won the bidding war against Johnson & Johnson (J&J) and acquired Guidant for $27B, the largest #medtech #acquisition at the time. However, after the acquisition, everything that could go wrong did go wrong. Guidant, already involved in lawsuits and government investigations over issues with its heart devices, continued to encounter problems and massive #recalls. Over the following years, Boston Scientific worked to resolve these issues, took substantial write-downs, and reported significant losses, leading to a sharp decline in its market cap. J&J also filed a #lawsuit seeking $7B in damages, accusing Guidant (now Boston Scientific) of breaking the original deal. At trial, Boston Scientific argued that J&J should not get any damages because it was better off losing the bidding war, admitting the acquisition was a bad deal. By 2010, many believed the company would never recover. By 2012, a company that once had a $34B valuation and made a $27B acquisition was worth only $8B, less than one-third of what it paid for Guidant.   𝐓𝐡𝐞 𝐂𝐨𝐦𝐞𝐛𝐚𝐜𝐤   Since 2012, Boston Scientific has undergone a significant transformation. Under new leadership, the company focused on organic #growth and market expansion by launching new products. It also shifted its acquisition strategy to smaller, tuck-in type acquisitions, typically valued at less than a billion dollars. Additionally, it made substantial improvements to its #culture, #values, and reputation, which ultimately enhanced its financial performance. Finally, in 2015, Boston Scientific paid $0.6B to J&J to settle its long-running lawsuit. Today, the company is firing on all cylinders. With a valuation exceeding $120B, Boston Scientific stands as one of the most valuable medical device companies, proving many skeptics wrong.   As 𝐑𝐨𝐜𝐤𝐲 𝐁𝐚𝐥𝐛𝐨𝐚 once said “It ain’t about how hard you hit. 𝐈𝐭’𝐬 𝐚𝐛𝐨𝐮𝐭 𝐡𝐨𝐰 𝐡𝐚𝐫𝐝 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐠𝐞𝐭 𝐡𝐢𝐭 𝐚𝐧𝐝 𝐤𝐞𝐞𝐩 𝐦𝐨𝐯𝐢𝐧𝐠 𝐟𝐨𝐫𝐰𝐚𝐫𝐝. That is how winning is done.” * Views and ideas are my own. The content that I provide here is public and intended to be educational only and is not endorsement or financial advice. I always encourage the readers to do their research.

When building a company-wide approach to extending your Life Sciences cash runway, CFOs and leadership teams must do the following:    - Understand investor expectations - Spend cash on what matters - Evaluate different scenarios for funding growth - Focus on right now Read more: https://lnkd.in/gBSGmhs5 #lifesciencecfo #cashmanagement 

Corner-office newcomers: 1st-time CEOs discuss challenges of running a biotech. There are common challenges including personal (loneliness at the top and balancing work/family), unearthing "blind spots" and measuring success: https://bit.ly/3YFPumC